Developer docs
API playgroundTry for free, no card

Search company profiles

One Biosciences

Full company profile

uuid0000mot

Namestring
One Biosciences
Legal namestring
One Biosciences SAS
Company typeenum
Private
Founded yearint
2020
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
single-cell transcriptomics, precision oncology, clinical diagnostics, biomarker discovery, AI drug development
Industry5 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAGANAC
Single-Cell & Spatial Omics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code3 codes
  • Medical Laboratories621511
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Precision Oncology Diagnostics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Clinical Diagnostic Services
TypeSubscription Recurring
Description

The company provides clinical-grade single-cell profiling services to healthcare providers and clinical institutions, delivering tumor analysis reports in under two weeks to support oncologists with treatment decision-making.

onebiosciences.fr
2Pharma & Biotech Partnership Services
TypeProfessional Services
Description

B2B services for pharmaceutical and biotech companies including biomarker identification, patient stratification, clinical trial optimization, and target prioritization. Revenue generated through research collaborations, co-development agreements, and service contracts.

onebiosciences.fr
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1OneMap
Description

Clinical-grade single-cell transcriptomic oncology platform that generates high-quality profiles of tumor, stromal and immune cells from clinical samples, delivering reports in under two weeks.

onebiosciences.fr
Core offering1 text field

One Biosciences operates the OneMap platform, an AI-powered clinical-grade single-cell transcriptomic profiling service that processes FFPE or frozen tissue samples to generate high-quality profiles of tumor, stromal, and immune cells, delivering clinician-ready reports in under two weeks. The company sells these profiling services to pharmaceutical and biotech companies for biomarker identification, patient stratification, and clinical trial support, and to clinical oncology institutions for treatment decision-making.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Clinical-grade reports delivered in under two weeks
+2 more records
Product overview1 text field

One Biosciences offers a unified platform called OneMap for AI-powered, clinical-grade single-cell profiling in precision oncology. The platform comprises the core OneMap Platform for single-cell transcriptomic analysis, which includes two integrated modules: Clinical Tumor Intelligence for oncologist decision support and Pharma & Biotech Partner Platform for drug development applications. The company also provides MAYA, a computational method for multi-modal pathway analysis published in Nature Communications. The platform processes clinical samples (FFPE or frozen tissue) and delivers clinician-ready reports in under two weeks using clinically trained AI foundation models.

Product and service3 records
1OneMap Platform
CategorySingle-Cell Analytics Platform
2Clinical Diagnostic Services
CategoryClinical Services
3Pharma & Biotech Partnership Services
CategoryDrug Development Services
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-22
Description

Collaboration partner in BOOST grant project to develop single-cell assay for ADC therapies. Combines Adcytherix's antibody-drug conjugate development expertise with One Biosciences' AI-powered single-cell profiling technology to analyze tumor samples and identify biomarkers associated with treatment response in oncology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-19
Description

Major partnership to implement single-cell analysis into clinical oncology practice using AI-powered solutions to predict treatment responses in cancer patients. Collaboration builds on previous feasibility studies with focus on integrating ultra-high-resolution tumor data into patient care workflows. Also collaborated on bladder cancer research project (April 2024) and urothelial cancer study presented at AACR 2025.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Founding institution where One Biosciences originated in 2017. Co-founder Céline Vallot heads the Dynamics of Epigenetic Plasticity group at Institut Curie. The company was created to turn proof-of-concept from Institut Curie research into a commercial platform. Institut Curie provided startup incubation support starting March 2021.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership to launch a single-cell research project on a rare kidney disease announced in November 2023, expanding the company's disease area focus beyond oncology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partner and incubator. Co-founders Magali Richard and David Schilansky from Home Biosciences helped sharpen the company's vision to make single-cell work on real clinical samples. Home Biosciences provided incubation support for company creation in 2020.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Leading provider of single-cell sequencing platforms (Chromium, Visium) used widely across academic and pharma oncology research. Direct competitor to OneMap in clinical single-cell profiling, with a much larger installed base and broader assay portfolio.

TypeDirect peer
Description

Single-cell RNA sequencing platform provider with scalable, fixation-based workflows (Evercode) that, like One Biosciences, target flexibility in sample handling for clinical and translational research. Comparable technology category and customer overlap in pharma biomarker discovery.

TypeDirect peer
Description

Single-cell multi-omics platform focused on oncology applications including measurable residual disease and tumor heterogeneity — directly adjacent to One Biosciences' clinical single-cell oncology positioning, with overlapping pharma/biotech and clinical customer base.

TypeDirect peer
Description

Provider of spatial transcriptomics and single-cell profiling solutions (GeoMx, CosMx) for oncology research and translational applications. Overlaps with One Biosciences on tumor microenvironment profiling and pharma biomarker services.

TypeBroad incumbent
Description

Established molecular diagnostics company providing comprehensive genomic profiling of solid tumors — a broad incumbent in clinical oncology diagnostics whose executive chairman (Dr. Vincent Miller) previously served as CMO. Compares as a large-scale reference point for clinical-grade tumor profiling and pharma partnerships.

6Tempus Labs
TypeBroad incumbent
Description

AI-driven precision medicine company combining multi-omics sequencing with clinical data for oncology decision support and pharma R&D — a broad incumbent whose OneMap-relevant overlap includes clinical tumor profiling and pharma data services, and which acquired Ambry Genetics (former employer of One's CBO).

TypeBroad incumbent
Description

Molecular profiling and AI-driven precision oncology company offering whole-exome, whole-transcriptome, and proteomic tumor analysis plus pharma services. Comparable in clinical tumor intelligence and pharma/CDx partnership model.

TypeEmerging player
Description

Specialist in spatial biology (PhenoCycler, PhenoImager) for tumor microenvironment characterization in research and clinical pharma. Emerging peer with partial overlap on single-cell/spatial tumor profiling for pharma biomarker work.

TypeEmerging player
Description

Cancer genomics company offering tumor profiling assays (e.g., NeXT Personal) for minimal residual disease and immunotherapy response monitoring. Comparable as a clinical-grade, pharma-services-oriented oncology genomics player.

TypeEmerging player
Description

AI-driven spatial biology company providing tumor microenvironment analysis for pharma drug development. Directly comparable in AI-oncology focus; CBO Vikas Ahuja previously led strategic partnerships there.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

One Biosciences

Precision Oncology Diagnosticsonebiosciences.fr

One Biosciences firmographics

Firmographics
Name
One Biosciences
Legal name
One Biosciences SAS
Website
https://onebiosciences.fr
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

One Biosciences industry classification

Industry
Product category
Precision Oncology Diagnostics
NAICS
Medical Laboratories (621511), Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAGANAC
Single-Cell & Spatial Omics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Single-cell transcriptomics
  • Precision oncology
  • Clinical diagnostics
  • Biomarker discovery
  • AI drug development

Where One Biosciences is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices2 records

Markets served

One Biosciences business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Clinical Diagnostic Services: The company provides clinical-grade single-cell profiling services to healthcare providers and clinical institutions, delivering tumor analysis reports in under two weeks to support oncologists with treatment decision-making.
  2. Pharma & Biotech Partnership Services: B2B services for pharmaceutical and biotech companies including biomarker identification, patient stratification, clinical trial optimization, and target prioritization. Revenue generated through research collaborations, co-development agreements, and service contracts.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

One Biosciences product offering

Product offering

Core offering

One Biosciences operates the OneMap platform, an AI-powered clinical-grade single-cell transcriptomic profiling service that processes FFPE or frozen tissue samples to generate high-quality profiles of tumor, stromal, and immune cells, delivering clinician-ready reports in under two weeks. The company sells these profiling services to pharmaceutical and biotech companies for biomarker identification, patient stratification, and clinical trial support, and to clinical oncology institutions for treatment decision-making.

Product overview

One Biosciences offers a unified platform called OneMap for AI-powered, clinical-grade single-cell profiling in precision oncology. The platform comprises the core OneMap Platform for single-cell transcriptomic analysis, which includes two integrated modules: Clinical Tumor Intelligence for oncologist decision support and Pharma & Biotech Partner Platform for drug development applications. The company also provides MAYA, a computational method for multi-modal pathway analysis published in Nature Communications. The platform processes clinical samples (FFPE or frozen tissue) and delivers clinician-ready reports in under two weeks using clinically trained AI foundation models.

Differentiator

Problem solved

Functional benefit

Brands

  • OneMap: Clinical-grade single-cell transcriptomic oncology platform that generates high-quality profiles of tumor, stromal and immune cells from clinical samples, delivering reports in under two weeks.

Products and services

  • OneMap Platform
  • Clinical Diagnostic Services
  • Pharma & Biotech Partnership Services

Quantifiable outcome

  • Clinical-grade reports delivered in under two weeks
  • +2 more outcomes

Companies that use One Biosciences

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

One Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

One Biosciences partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • AdcytherixcoreStrategic or Co-development Partner · 22 June 2026Collaboration partner in BOOST grant project to develop single-cell assay for ADC therapies. Combines Adcytherix's antibody-drug conjugate development expertise with One Biosciences' AI-powered single-cell profiling technology to analyze tumor samples and identify biomarkers associated with treatment response in oncology.
  • Gustave RoussycoreStrategic or Co-development Partner · 19 May 2026Major partnership to implement single-cell analysis into clinical oncology practice using AI-powered solutions to predict treatment responses in cancer patients. Collaboration builds on previous feasibility studies with focus on integrating ultra-high-resolution tumor data into patient care workflows. Also collaborated on bladder cancer research project (April 2024) and urothelial cancer study presented at AACR 2025.
  • Institut CuriecoreStrategic or Co-development PartnerFounding institution where One Biosciences originated in 2017. Co-founder Céline Vallot heads the Dynamics of Epigenetic Plasticity group at Institut Curie. The company was created to turn proof-of-concept from Institut Curie research into a commercial platform. Institut Curie provided startup incubation support starting March 2021.
  • AP-HP (Assistance Publique-Hôpitaux de Paris)minorStrategic or Co-development PartnerPartnership to launch a single-cell research project on a rare kidney disease announced in November 2023, expanding the company's disease area focus beyond oncology.
  • Home BiosciencescoreStrategic or Co-development PartnerStrategic partner and incubator. Co-founders Magali Richard and David Schilansky from Home Biosciences helped sharpen the company's vision to make single-cell work on real clinical samples. Home Biosciences provided incubation support for company creation in 2020.

Scale indicators3 records

Recent moves9 records

Expansion highlights6 records

One Biosciences competitors and assessment

Company assessment

Direct peers

  • 10x Genomics: Leading provider of single-cell sequencing platforms (Chromium, Visium) used widely across academic and pharma oncology research. Direct competitor to OneMap in clinical single-cell profiling, with a much larger installed base and broader assay portfolio.
  • Parse Biosciences: Single-cell RNA sequencing platform provider with scalable, fixation-based workflows (Evercode) that, like One Biosciences, target flexibility in sample handling for clinical and translational research. Comparable technology category and customer overlap in pharma biomarker discovery.
  • Mission Bio: Single-cell multi-omics platform focused on oncology applications including measurable residual disease and tumor heterogeneity — directly adjacent to One Biosciences' clinical single-cell oncology positioning, with overlapping pharma/biotech and clinical customer base.
  • NanoString Technologies (Bruker Spatial Biology): Provider of spatial transcriptomics and single-cell profiling solutions (GeoMx, CosMx) for oncology research and translational applications. Overlaps with One Biosciences on tumor microenvironment profiling and pharma biomarker services.

Broad incumbents

  • Foundation Medicine (Roche): Established molecular diagnostics company providing comprehensive genomic profiling of solid tumors — a broad incumbent in clinical oncology diagnostics whose executive chairman (Dr. Vincent Miller) previously served as CMO. Compares as a large-scale reference point for clinical-grade tumor profiling and pharma partnerships.
  • Tempus Labs: AI-driven precision medicine company combining multi-omics sequencing with clinical data for oncology decision support and pharma R&D — a broad incumbent whose OneMap-relevant overlap includes clinical tumor profiling and pharma data services, and which acquired Ambry Genetics (former employer of One's CBO).
  • Caris Life Sciences: Molecular profiling and AI-driven precision oncology company offering whole-exome, whole-transcriptome, and proteomic tumor analysis plus pharma services. Comparable in clinical tumor intelligence and pharma/CDx partnership model.

Emerging players

  • Akoya Biosciences: Specialist in spatial biology (PhenoCycler, PhenoImager) for tumor microenvironment characterization in research and clinical pharma. Emerging peer with partial overlap on single-cell/spatial tumor profiling for pharma biomarker work.
  • Personalis: Cancer genomics company offering tumor profiling assays (e.g., NeXT Personal) for minimal residual disease and immunotherapy response monitoring. Comparable as a clinical-grade, pharma-services-oriented oncology genomics player.
  • Nucleai: AI-driven spatial biology company providing tumor microenvironment analysis for pharma drug development. Directly comparable in AI-oncology focus; CBO Vikas Ahuja previously led strategic partnerships there.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

One Biosciences social profiles

Digital presence

One Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

One Biosciences leadership team

Management profile

Number of profiles

Profiles9 records

One Biosciences funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

One Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about One Biosciences

What does One Biosciences do?

One Biosciences operates the OneMap platform, an AI-powered clinical-grade single-cell transcriptomic profiling service that processes FFPE or frozen tissue samples to generate high-quality profiles of tumor, stromal, and immune cells, delivering clinician-ready reports in under two weeks. The company sells these profiling services to pharmaceutical and biotech companies for biomarker identification, patient stratification, and clinical trial support, and to clinical oncology institutions for treatment decision-making.

Is One Biosciences a public or private company?

One Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was One Biosciences founded?

One Biosciences was founded in 2020. It employs 11 to 50 people.

Where is One Biosciences based?

One Biosciences is headquartered in Paris, France, in the Europe region.

How does One Biosciences make money?

Two revenue lines are on record. Clinical Diagnostic Services are the primary driver. The others are pharma & Biotech Partnership Services.

Who are One Biosciences's main competitors?

Direct peers on record are 10x Genomics, Parse Biosciences, Mission Bio and NanoString Technologies (Bruker Spatial Biology). Broad incumbents are Foundation Medicine (Roche), Tempus Labs and Caris Life Sciences. Emerging players are Akoya Biosciences, Personalis and Nucleai.

Does One Biosciences have an API?

No public API is recorded for One Biosciences.

What industry is One Biosciences in?

One Biosciences's product category is Precision Oncology Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAGANAC, Single-Cell & Spatial Omics Services. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogNew Research from One Biosciences Shows Single-Cell Profiling Can Identify Which Ovarian Cancer Tumors are Predisposed to Chemotherapy ResistanceResearchers from One Biosciences and partners found that ovarian cancer tumor cells are epigenetically primed for chemotherapy resistance, with initial tumor profiles predicting survival. Single-cell profiling of FFPE biopsy samples can identify resistance states, enabling personalized treatment strategies.FinancialContent Business PageNew Research from One Biosciences Shows Single-Cell Profiling Can Identify Which Ovarian Cancer Tumors are Predisposed to Chemotherapy ResistanceOne Biosciences announced data showing ovarian cancer tumor cells are epigenetically primed to resist chemotherapy, with single-cell profiling at diagnosis identifying resistant profiles. The study found higher initial resistance states predicted poorer survival in high-grade serous ovarian cancer, and the technology can be applied to standard FFPE biopsy samples.FinSMEsOne Biosciences Receives €3.3M in Non-Dilutive Public FundingOne Biosciences received €3.3M in non-dilutive public funding from Bpifrance under the i-Démo 5 call. The grant finances the CAST project, a four-year clinical translation program with Institut Curie to industrialize its single-cell profiling platform for triple-negative breast cancer. The company will use funds to validate biomarkers and prepare for CE-IVD approvals.Pulse 2.0One Biosciences Secures €3.3 Million To Develop AI-Powered Single-Cell Diagnostic For Triple-Negative Breast CancerOne Biosciences and Institut Curie secured €3.3 million from France 2030's i-Démo program to develop a single-cell diagnostic for triple-negative breast cancer. The four-year project advances OneMap technology, which uses AI and single-cell transcriptomics to guide treatment decisions. The platform aims to produce clinically actionable reports within two weeks from standard hospital biopsies.FinanzNachrichten.deOne Biosciences erhält 3,3 Millionen Euro aus i-Démo 5 im Rahmen von Frankreich 2030, um in Zusammenarbeit mit dem Institut Curie die Entwicklung der ersten Einzelzelldiagnostik für triple-negativen BOne Biosciences and Institut Curie received 3.3 million euros from Bpifrance's i-Démo 5 program to develop a single-cell diagnostic for triple-negative breast cancer. The four-year CAST project will bring OneMap, an in-vitro test, to market, aiming to guide treatment decisions for TNBC patients.Business Wire BlogOne Biosciences Receives €3,3 Million Funding Under i-Démo 5 From France 2030 to Accelerate Development of First Single-Cell Diagnostic for Triple-Negative Breast Cancer, in Collaboration With InstituOne Biosciences and Institut Curie received €3.3 million from France 2030's i-Démo program for the CAST project, developing a single-cell diagnostic for triple-negative breast cancer. The project aims to commercialize OneMap, a platform that analyzes tumors at single-cell resolution to guide treatment decisions. The initiative will build the world's largest clinically annotated single-cell dataset in TNBC.Institut-CurieOne Biosciences, a spin-off of Institut Curie, secures €3.3 million to develop the first single-cell diagnostic for triple-negative breast cancerOne Biosciences, a spin-off of Institut Curie, secured €3.3 million from Bpifrance under France 2030 to develop the CAST project, a single-cell diagnostic for triple-negative breast cancer. The four-year program aims to commercialize OneMap™, an in vitro diagnostic test, and build the world's largest clinically annotated single-cell dataset for TNBC.BioSpaceOne Biosciences Announces Data Validating New Method for Single-Cell Transcriptomic Tumor Profiling from Clinical Pathology SamplesOne Biosciences announced data validating its OneMap platform for single-cell RNA profiling from routine FFPE pathology slides. The study, a preprint on BiorXiv, included 88 single-nucleus experiments across six cancer types, with high technical reproducibility and automated immune infiltration estimates matching pathologists' assessments.AijournOne Biosciences Announces Data Validating New Method for Single-Cell Transcriptomic Tumor Profiling from Clinical Pathology SamplesOne Biosciences announced validation data showing that single-cell RNA expression profiles can be generated from standard FFPE pathology specimens used in routine cancer care, using their proprietary OneMap™ platform. The study, conducted with collaborators at Centre Léon Bérard, Hôpital Bichat–Claude Bernard, Institut Curie, and Memorial Sloan Kettering Cancer Center, validated the workflow across 88 specimens spanning six cancer types with high technical reproducibility (median correlation > 0.92). The company states this enables single-cell profiling for clinical use without requiring specialized samples, creating a sample-to-report solution that can support more targeted clinical trials and improve patient care.Business Wire BlogOne Biosciences Announces Data Validating New Method for Single-Cell Transcriptomic Tumor Profiling from Clinical Pathology SamplesOne Biosciences announced data validating its OneMap™ platform for generating single-cell RNA expression profiles from routine formalin-fixed paraffin-embedded (FFPE) pathology specimens, enabling single-cell analysis from standard clinical samples. The study, conducted with four institutions across 88 specimens spanning six cancer types, demonstrated high technical reproducibility (median correlation >0.92) and succeeded on archival blocks up to a decade old and ultra-low-input biopsies. The platform eliminates batch processing requirements of older methods, producing standardized individual patient reports and quantifying clinically relevant antibody-drug-conjugate targets, with potential to guide more targeted clinical trials and improve patient care.